Please assess the completion status of the following clinical trial:

Trial Title: Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Receipt of Menactra vaccine during the study period.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Menactra Vaccine Recipients (Type: None): Participants who received Menactra vaccine as part of routine medical care during the study period in Kaiser Permanente.
- Age-Matched Control (Type: None): Each individual receiving Menactra vaccine served as their own control for evaluation of acute (Days 0-30) events (short-term surveillance). For the 6-month (long-term) surveillance, for each person receiving Menactra vaccine, a control matched on age (± 1 year), sex, and month of vaccination was selected who received a received tetanus and diphtheria toxoids (Td), hepatitis A, hepatitis B, or hepatitis A/hepatitis B combination vaccine as part of routine medical care during the same month 1 year earlier in Kaiser Permanente

Based on this trial design, predict the completion outcome and termination type (if applicable).